首页 正文

Real-world clinical outcomes, genetic testing patterns, and treatment patterns of patients with metastatic castration-resistant prostate cancer treated with olaparib monotherapy in the United States

{{output}}
Introduction: The PROfound clinical trial showed that patients with metastatic castration-resistant prostate cancer (mCRPC) who harbored homologous recombination repair gene mutations (HRRm) benefited from receiving olaparib mono... ...